Delivery Order SPE2DB22D1202-SPE2DB25FVFZ4
- Not listed
- The U.S. Department of Defense's Medical Supply Chain (DLA Troop Support Medical) awarded a firm-fixed-price delivery order to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of Dupixent 300 mg/2 ml syringes. The order has a ceiling value of $3,342.10 and an ultimate completion date of May 10, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the Defense Logistics Agency...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of Dupixent 300 mg/2 ml syringes. The order, valued at $10,387.04, will support military treatment programs and facilities through March 2024. This award is part of a larger indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp with a potential value of $999,999,999.00 and a performance period through...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,302.48 on July 25, 2025, for the supply of Dupixent 300 mg/2 ml syringes. The contract is competitively awarded with no set-aside designation and carries an ultimate completion date of July 28, 2025. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Dupixent 300 mg/2 ml syringes. The contract is valued at $22,619.31 and represents a firm fixed-price delivery order with an ultimate completion date of July 22, 2025. The performance location is the company's corporate office in Conshohocken, Pennsylvania. This is a non-set-aside award, indicating it was competitively awarded. The delivery order is issued under...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $44,107.24 under firm fixed-price terms. The contract, which is classified as a child order under a larger indefinite delivery vehicle, requires completion by July 31, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $26,119.30 for Dupixent 300 mg/2 ml pen (2 ml) under a firm fixed price contract with the Defense Logistics Agency's Medical Supply Chain. The award was made on July 30, 2025, with an ultimate completion date of July 31, 2025, and represents a non-set-aside, competitively awarded contract. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $11,735.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on July 30, 2025, with an ultimate completion date of July 31, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,709.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on July 21, 2025. This firm fixed-price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The contract was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL syringes valued at $4,991.39. This non-set-aside, firm fixed-price delivery order is scheduled for completion by July 28, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a discrete purchase under AmerisourceBergen's existing contract vehicle with the DLA. AmerisourceBergen Drug Corp is a major...
- The U.S. government agency, the Defense Logistics Agency (DLA) Troop Support Medical, awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Dupixent 300 mg/2 ml syringes. The contract, valued at $23,211.99, has an ultimate completion date of June 7, 2022. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) awarded by DLA with a potential value of $999,999,999.00 and a...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVFZ4Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency for the supply of Dupixent 300 mg/2 ml syringes (2 ml). The contract is valued at $3,960.88 with a firm fixed price and an ultimate completion date of July 31, 2025. This award represents a competitive, non-set-aside procurement and is classified as a child contract, indicating it derives from a larger contract vehicle. The Defense Logistics Agency, operating under the Department of Defense, is responsible for supply chain management and medical procurement for military and defense operations. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The prime contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Dupixent is a biologic medication used primarily for immunological conditions, and this procurement supports the Defense Health Agency and related government healthcare systems in fulfilling their medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 7/30/25 |